Search Results - "Minartz, C."

  • Showing 1 - 13 results of 13
Refine Results
  1. 1

    Budget impact of the Oncotype DX® test compared to other gene expression tests in patients with early breast cancer in Germany by Lux, M.P., Minartz, C., Müller-Huesmann, H., Sandor, M.F., Herrmann, K.H., Radeck-Knorre, S., Neubauer, A.S.

    “…•Gene expression tests have a high impact on the total value of breast cancer treatment.•Oncotype DX test can help to avoid unnecessary chemotherapy and…”
    Get full text
    Journal Article
  2. 2
  3. 3
  4. 4

    Kosten und Nutzen der Darmkrebsprävention by Neubauer, G., Minartz, C.

    Published in Der Onkologe (01-10-2010)
    “…Zusammenfassung Die Darmkrebsprävention rettet Leben und ist darüber hinaus auch aus ökonomischen Gesichtspunkten positiv zu bewerten. Anhand eines…”
    Get full text
    Journal Article
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10

    Quality Assured Use of Pharmaceuticals: Does German Gba Follow Ema? by Menzler, Jzzz, Minartz, C, Thienel, P, Neubauer, AS

    Published in Value in health (01-10-2017)
    “…OBJECTIVES: After receiving the EMA approval for Europe, it is mandatory for pharmaceuticals in Germany to complete the AMNOG process to receive reimbursement…”
    Get full text
    Journal Article
  11. 11

    Cost-effectiveness of early treatment of ACPA-positive rheumatoid arthritis patients with abatacept by Neubauer, Aljoscha S, Minartz, Christof, Herrmann, Kirsten H, Baerwald, Christoph G O

    Published in Clinical and experimental rheumatology (01-05-2018)
    “…Studies have reported that the presence of elevated anti-citrullinated protein antibodies (ACPA)/RF levels, together with joint erosions, is associated with…”
    Get full text
    Journal Article
  12. 12
  13. 13

    Economic Short-Term Cost Model for Stereotactic Radiotherapy of Neovascular AMD by Neubauer, A S, Reznicek, L, Minartz, C, Ziemssen, F

    Published in Klinische Monatsblatter fur Augenheilkunde (01-08-2016)
    “…Stereotactic radiation therapy (Oraya, OT) is available as a second line therapy for patients who, despite intensive anti-VEGF therapy for neovascular AMD, do…”
    Get more information
    Journal Article